Related Experiment Videos
Platelet-rich plasmapheresis: a meta-analysis of clinical outcomes and costs
1Industrial Relations Center, University of Minnesota, Minneapolis 55455-0430, USA.
Insights
Platelet-rich plasmapheresis (PRP) improves patient outcomes after cardiopulmonary bypass (CPB) surgery. This meta-analysis shows PRP reduces blood product use, shortens hospital stays, and saves costs, benefiting patients and healthcare economics.
Area of Science:
- Cardiovascular Surgery
- Transfusion Medicine
- Health Economics
Background:
- Platelet-rich plasmapheresis (PRP) is utilized before cardiopulmonary bypass (CPB) to enhance hemostasis and reduce allogeneic blood exposure.
- Meta-analysis is employed to synthesize evidence on PRP's clinical and economic impacts.
Purpose of the Study:
- To evaluate the impact of PRP on clinical outcomes following CPB surgery.
- To assess the economic implications of PRP use by analyzing DRG payment rates and national average costs.
Main Methods:
- A meta-analysis was conducted, integrating data from 20 published research studies.
- Clinical outcomes, DRG payment rates, and national average costs were collected and analyzed.
Main Results:
- PRP significantly improved all analyzed clinical outcomes compared to control groups not receiving PRP.
- Key improvements included reduced blood product usage (especially packed red blood cells), shorter hospital and intensive care stays, faster extubation, and lower incidences of cardiovascular accidents and reoperations.
- Estimated cost savings per patient ranged from $2,505.00 to $4,209.00.
Conclusions:
- The use of PRP prior to CPB surgery leads to demonstrably better clinical outcomes for patients.
- Implementing PRP technology during CPB surgery results in overall cost savings, highlighting the economic benefits of initial technological investment.
Abstract:
Platelet-rich plasmapheresis (PRP) just prior to cardiopulmonary bypass (CPB) surgery is used to improve post CPB hemostasis and to minimize the risks associated with exposure to allogeneic blood and its components. Meta-analysis examines evidence of PRP's impact on clinical outcomes by integrating the results across published research studies. Data on clinical outcomes was collected from 20 published studies. These outcomes, DRG payment rates, and current national average costs were used to examine the impact of PRP on costs. This study provides evidence that the use of PRP results in improved clinical outcomes when compared to the identical control groups not receiving PRP. These improved clinical outcomes result in subsequent lower costs per patient in the PRP groups. All clinical outcomes analyzed were improved: blood product usage, length of stay, intensive care stay, time to extubation, incidence of cardiovascular accident, and incidence of reoperation. The most striking differences occur in use of all blood products, particularly packed red blood cells. This study provides an example of how initial expenditure on technology used during CPB results in overall cost savings. Estimated cost savings range from $2,505.00 to $4,209.00. More importantly, patients benefit from improved clinical outcomes.